HERMANSON, GARY G.,GEALL, ANDREW J.,WLOCH, MARY KOPKE
申请号：
CA2508228
公开号：
CA2508228C
申请日:
2003.12.19
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
The invention is related to polynucleotide-based cytomegalovirus vaccines. Inparticular, the invention is plasmids operably encoding HCMV antigens, inwhich the naturally-occurring coding regions for the HCMV antigens have beenmodified for improved translation in human or other mammalian cells throughcodon optimization. HCMV antigens which are useful in the invention include,but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variantsor derivatives of either of these antigens. In certain embodiments, sequenceshave been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and themembrane anchor and endocellular domains in gB. The invention is furtherdirected to methods to induce an immune response to HCMV in a mammal, forexample, a human, comprising delivering a plasmid encoding a codon-optimizedHCMV antigen as described above. The invention is also directed topharmaceutical compositions comprising plasmids encoding a codon-optimizedHCMV antigen as described above, and further comprising adjuvants, excipients,or immune modulators.
